<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01628042</url>
  </required_header>
  <id_info>
    <org_study_id>4618-014</org_study_id>
    <nct_id>NCT01628042</nct_id>
  </id_info>
  <brief_title>A Single Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Participants With Renal Insufficiency (MK-4618-014)</brief_title>
  <official_title>An Open-Label, Single-Dose Study to Investigate the Pharmacokinetics of MK-4618 in Patients With Renal Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the impact of impaired renal function on the plasma
      pharmacokinetics of vibegron (MK-4618) to guide use of vibegron in clinical trials in
      participants with overactive bladder and to guide recommendations on potential dosing
      adjustments for individuals with varying degrees of renal impairment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve From 0 to Infinity (AUC0-∞) After a Single Oral Dose of Vibegron 100 mg</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 120, 216, and 336 hours postdose</time_frame>
    <description>Blood samples were collected predose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 120, 216, and 336 hours after dosing in order to determine AUC0-∞ after a single oral dose of vibegron 100 mg.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) After a Single Oral Dose of Vibegron 100 mg</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 120, 216, and 336 hours postdose</time_frame>
    <description>Blood samples were collected predose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 120, 216, and 336 hours after dosing in order to determine Cmax after a single oral dose of vibegron 100 mg.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Total Body Clearance (CL/F) After a Single Oral Dose of Vibegron 100 mg</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 120, 216, and 336 hours postdose</time_frame>
    <description>Blood samples were collected predose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 120, 216, and 336 hours after dosing in order to determine CL/F after a single oral dose of vibegron 100 mg.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Participants With Severe Renal Insufficiency</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose of vibegron 100 mg on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants With Moderate Renal Insufficiency</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose of vibegron 100 mg on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants With Mild Renal Insufficiency</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose of vibegron 100 mg on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Matched Control Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a single oral dose of vibegron 100 mg on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vibegron 100 mg</intervention_name>
    <description>Vibegron tablets, orally, on Day 1</description>
    <arm_group_label>Participants With Severe Renal Insufficiency</arm_group_label>
    <arm_group_label>Participants With Moderate Renal Insufficiency</arm_group_label>
    <arm_group_label>Participants With Mild Renal Insufficiency</arm_group_label>
    <arm_group_label>Healthy Matched Control Participants</arm_group_label>
    <other_name>MK-4618</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria - Renal Impaired Patients

          -  Body mass index (BMI) ≤40 kg/m^2

          -  Clinical diagnosis of renal insufficiency

          -  Stable baseline health

        Inclusion Criteria - Healthy Subjects

        - Stable baseline health

        Exclusion Criteria - Renal Impaired Patients

          -  History of clinically significant endocrine, gastrointestinal, cardiovascular,
             hematological, immunological, respiratory, or genitourinary disease

          -  History of recent stroke, chronic seizures, or major neurological disorder

          -  Demonstrated or suspected renal artery stenosis

          -  Renal transplant or nephrectomy

          -  History of cancer excepting certain skin or cervical cancers or cancers that were
             successfully treated 10 or more years prior to screening

          -  History of significant multiple and/or severe allergies (including latex allergy), or
             anaphylactic reaction or significant intolerability to prescription or
             non-prescription drugs or food

          -  Unable to refrain from or anticipates the use of any medication including prescription
             and non-prescription drugs or herbal remedies beginning approximately 2 weeks prior to
             administration of study drug, throughout the study, and until the post study visit

          -  Unable to avoid taking diuretics within 4 hours prior to dosing and 4 hours post
             dosing; must be on a stable dose for at least approximately 2 weeks (or 5 half-lives
             of the compound, whichever is longer)

          -  Unwilling to refrain from consuming any food or drink/beverage containing grapefruit
             or grapefruit juice, apple or orange juice, vegetables from the mustard green family
             (e.g., kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts,
             mustard), and charbroiled meats 2 weeks prior to dosing until the post-study visit

          -  Consumption of excessive amounts of alcohol, defined as greater than 3 glasses of
             alcoholic beverages (1 glass is approximately equivalent to: beer [284 mL/10 ounces],
             wine [125 mL/4 ounces], or distilled spirits [25 mL/1 ounce]) per day

          -  Consumption of excessive amounts, defined as greater than 6 servings (1 serving is
             approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, or other
             caffeinated beverages per day

          -  Major surgery, donation or loss of 1 unit of blood (approximately 500 mL) within 4
             weeks prior to administration of study drug

          -  Plasma donation within 7 days prior to administration of study drug

          -  Current regular user (including &quot;recreational use&quot;) of any illicit drugs or has a
             history of drug (including alcohol) abuse within approximately 12 months

          -  Nursing mother

          -  Participation in another investigational study within 4 weeks of study enrollment

        Exclusion Criteria - Healthy Subjects

          -  History of clinically significant endocrine, gastrointestinal, cardiovascular,
             hematological, hepatic, immunological, renal, respiratory, or genitourinary
             abnormalities or diseases

          -  History of stroke, chronic seizures, or major neurological disorder

          -  History of cancer excepting certain skin or cervical cancers or cancers that were
             successfully treated 10 or more years prior to screening

          -  History of significant multiple and/or severe allergies (including latex allergy), or
             anaphylactic reaction or significant intolerability to prescription or
             non-prescription drugs or food

          -  Unable to refrain from or anticipates the use of any medication including prescription
             and non-prescription drugs or herbal remedies beginning approximately 2 weeks prior to
             administration of the dose of study drug, throughout the study, until the post study
             visit

          -  Unwilling to refrain from consuming any food or drink/beverage containing grapefruit
             or grapefruit juice, apple or orange juice, vegetables from the mustard green family
             (e.g., kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts,
             mustard), and charbroiled meats 2 weeks prior to dosing until the post study visit

          -  Consumption of excessive amounts of alcohol, defined as greater than 3 glasses of
             alcoholic beverages (1 glass is approximately equivalent to: beer [284 mL/10 ounces],
             wine [125 mL/4 ounces], or distilled spirits [25 mL/1 ounce]) per day

          -  Consumption of excessive amounts, defined as greater than 6 servings (1 serving is
             approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, or other
             caffeinated beverages per day

          -  Major surgery, donation or loss of 1 unit of blood (approximately 500 mL) within 4
             weeks prior to administration of study drug

          -  Plasma donation within 7 days prior to administration of study drug

          -  Current regular user (including &quot;recreational use&quot;) of any illicit drugs or has a
             history of drug (including alcohol) abuse within approximately 12 months

          -  Nursing mother

          -  Participation in another investigational study within 4 weeks of study enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2012</study_first_submitted>
  <study_first_submitted_qc>June 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2012</study_first_posted>
  <results_first_submitted>June 27, 2016</results_first_submitted>
  <results_first_submitted_qc>June 27, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 9, 2016</results_first_posted>
  <last_update_submitted>August 19, 2016</last_update_submitted>
  <last_update_submitted_qc>August 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Participants With Severe Renal Insufficiency</title>
          <description>Participants received a single oral dose of vibegron 100 mg on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>Participants With Moderate Renal Insufficiency</title>
          <description>Participants received a single oral dose of vibegron 100 mg on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>Participants With Mild Renal Insufficiency</title>
          <description>Participants received a single oral dose of vibegron 100 mg on Day 1.</description>
        </group>
        <group group_id="P4">
          <title>Healthy Matched Control Participants</title>
          <description>Participants received a single oral dose of vibegron 100 mg on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Participants With Severe Renal Insufficiency</title>
          <description>Participants received a single oral dose of vibegron 100 mg on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>Participants With Moderate Renal Insufficiency</title>
          <description>Participants received a single oral dose of vibegron 100 mg on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Participants With Mild Renal Insufficiency</title>
          <description>Participants received a single oral dose of vibegron 100 mg on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>Healthy Matched Control Participants</title>
          <description>Participants received a single oral dose of vibegron 100 mg on Day 1.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" lower_limit="53" upper_limit="75"/>
                    <measurement group_id="B2" value="64" lower_limit="50" upper_limit="74"/>
                    <measurement group_id="B3" value="66" lower_limit="59" upper_limit="75"/>
                    <measurement group_id="B4" value="57" lower_limit="51" upper_limit="70"/>
                    <measurement group_id="B5" value="63" lower_limit="50" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve From 0 to Infinity (AUC0-∞) After a Single Oral Dose of Vibegron 100 mg</title>
        <description>Blood samples were collected predose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 120, 216, and 336 hours after dosing in order to determine AUC0-∞ after a single oral dose of vibegron 100 mg.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 120, 216, and 336 hours postdose</time_frame>
        <population>Per Protocol (PP) population, which included participants who complied with the protocol sufficiently to ensure that the data were likely to exhibit the effects of treatment, according to the underlying scientific model.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Severe Renal Insufficiency</title>
            <description>Participants received a single oral dose of vibegron 100 mg on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Participants With Moderate Renal Insufficiency</title>
            <description>Participants received a single oral dose of vibegron 100 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Participants With Mild Renal Insufficiency</title>
            <description>Participants received a single oral dose of vibegron 100 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Healthy Matched Control Participants</title>
            <description>Participants received a single oral dose of vibegron 100 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From 0 to Infinity (AUC0-∞) After a Single Oral Dose of Vibegron 100 mg</title>
          <description>Blood samples were collected predose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 120, 216, and 336 hours after dosing in order to determine AUC0-∞ after a single oral dose of vibegron 100 mg.</description>
          <population>Per Protocol (PP) population, which included participants who complied with the protocol sufficiently to ensure that the data were likely to exhibit the effects of treatment, according to the underlying scientific model.</population>
          <units>nM•hr</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6337.17" lower_limit="4940.96" upper_limit="8127.91"/>
                    <measurement group_id="O2" value="7137.53" lower_limit="5615.70" upper_limit="9071.77"/>
                    <measurement group_id="O3" value="5156.07" lower_limit="4045.44" upper_limit="6571.60"/>
                    <measurement group_id="O4" value="3466.04" lower_limit="2663.08" upper_limit="4511.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric least-squares mean ratio</param_type>
            <param_value>1.83</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.36</ci_lower_limit>
            <ci_upper_limit>2.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric least-squares mean ratio</param_type>
            <param_value>2.06</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.55</ci_lower_limit>
            <ci_upper_limit>2.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric least-squares mean ratio</param_type>
            <param_value>1.49</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.11</ci_lower_limit>
            <ci_upper_limit>2.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) After a Single Oral Dose of Vibegron 100 mg</title>
        <description>Blood samples were collected predose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 120, 216, and 336 hours after dosing in order to determine Cmax after a single oral dose of vibegron 100 mg.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 120, 216, and 336 hours postdose</time_frame>
        <population>PP population, which included participants who complied with the protocol sufficiently to ensure that the data were likely to exhibit the effects of treatment, according to the underlying scientific model.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Severe Renal Insufficiency</title>
            <description>Participants received a single oral dose of vibegron 100 mg on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Participants With Moderate Renal Insufficiency</title>
            <description>Participants received a single oral dose of vibegron 100 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Participants With Mild Renal Insufficiency</title>
            <description>Participants received a single oral dose of vibegron 100 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Healthy Matched Control Participants</title>
            <description>Participants received a single oral dose of vibegron 100 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) After a Single Oral Dose of Vibegron 100 mg</title>
          <description>Blood samples were collected predose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 120, 216, and 336 hours after dosing in order to determine Cmax after a single oral dose of vibegron 100 mg.</description>
          <population>PP population, which included participants who complied with the protocol sufficiently to ensure that the data were likely to exhibit the effects of treatment, according to the underlying scientific model.</population>
          <units>nM</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="342.83" lower_limit="232.00" upper_limit="506.62"/>
                    <measurement group_id="O2" value="404.50" lower_limit="277.65" upper_limit="589.30"/>
                    <measurement group_id="O3" value="473.01" lower_limit="323.26" upper_limit="692.12"/>
                    <measurement group_id="O4" value="240.80" lower_limit="159.24" upper_limit="364.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric least-squares mean ratio</param_type>
            <param_value>1.42</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>2.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric least-squares mean ration</param_type>
            <param_value>1.68</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.07</ci_lower_limit>
            <ci_upper_limit>2.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric least-squares mean ratio</param_type>
            <param_value>1.96</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.23</ci_lower_limit>
            <ci_upper_limit>3.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Total Body Clearance (CL/F) After a Single Oral Dose of Vibegron 100 mg</title>
        <description>Blood samples were collected predose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 120, 216, and 336 hours after dosing in order to determine CL/F after a single oral dose of vibegron 100 mg.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 120, 216, and 336 hours postdose</time_frame>
        <population>PP population, which included participants who complied with the protocol sufficiently to ensure that the data were likely to exhibit the effects of treatment, according to the underlying scientific model.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Severe Renal Insufficiency</title>
            <description>Participants received a single oral dose of vibegron 100 mg on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Participants With Moderate Renal Insufficiency</title>
            <description>Participants received a single oral dose of vibegron 100 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Participants With Mild Renal Insufficiency</title>
            <description>Participants received a single oral dose of vibegron 100 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Healthy Matched Control Participants</title>
            <description>Participants received a single oral dose of vibegron 100 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Total Body Clearance (CL/F) After a Single Oral Dose of Vibegron 100 mg</title>
          <description>Blood samples were collected predose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 120, 216, and 336 hours after dosing in order to determine CL/F after a single oral dose of vibegron 100 mg.</description>
          <population>PP population, which included participants who complied with the protocol sufficiently to ensure that the data were likely to exhibit the effects of treatment, according to the underlying scientific model.</population>
          <units>L/hr</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.5" lower_limit="27.68" upper_limit="45.53"/>
                    <measurement group_id="O2" value="31.5" lower_limit="24.80" upper_limit="40.06"/>
                    <measurement group_id="O3" value="43.6" lower_limit="34.23" upper_limit="55.61"/>
                    <measurement group_id="O4" value="64.9" lower_limit="49.87" upper_limit="84.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric least squares mean ratio</param_type>
            <param_value>0.55</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.41</ci_lower_limit>
            <ci_upper_limit>0.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric least squares mean ratio</param_type>
            <param_value>0.49</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.36</ci_lower_limit>
            <ci_upper_limit>0.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric least squares mean ratio</param_type>
            <param_value>0.67</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>0.90</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 336 hours post-dose</time_frame>
      <desc>The All Subjects as Treated (AST) population, which consisted of all participants who received at least 1 dose of the investigational drug, was used for the safety analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>Participants With Severe Renal Insufficiency</title>
          <description>Participants received a single oral dose of vibegron 100 mg on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>Participants With Moderate Renal Insufficiency</title>
          <description>Participants received a single oral dose of vibegron 100 mg on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>Participants With Mild Renal Insufficiency</title>
          <description>Participants received a single oral dose of vibegron 100 mg on Day 1.</description>
        </group>
        <group group_id="E4">
          <title>Healthy Matched Control Participants</title>
          <description>Participants received a single oral dose of vibegron 100 mg on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

